【LKL 0182 交流专区】

Tony-Pua

0182                 LKL                 LKL INTERNATIONAL BERHAD

Quarterly rpt on consolidated results for the financial period ended 30/04/2018

Quarter: 4th Quarter Financial Year End: 30/04/2018 Report Status: Unaudited Submitted By: Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period 30/04/2018 30/04/2017 30/04/2018 30/04/2017 RM '000 RM '000 RM '000 RM '000 1 Revenue 7,479 6,091 29,716 33,893 2 Profit/Loss Before Tax (1,641) 283 (1,202) 6,052 3 Profit/(loss) attributable to ordinary equity holders of the parent (1,510) 215 (1,098) 4,479 4 Net Profit/Loss For The Period (1,542) 215 (1,329) 4,477 5 Basic Earnings/Loss Per Shares (sen) (0.35) 0.05 (0.26) 1.05 6 Dividend Per Share (sen) 0.00 0.00 0.00 0.00 As At End of Current Quarter As At Preceding Financial Year End 7 Net Assets Per Share (RM) 0.1400 0.1400

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "COMPANY")- CONTRACT AWARDED TO LKL ADVANCE METALTECH SDN. BHD. ("LKLAM"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, FOR THE SUPPLY AND DELIVERY OF MEDICAL/HEALTHCARE BEDS AND MEDICAL PERIPHERALS
1. INTRODUCTION The Board of Directors of LKL International is pleased to announce that LKLAM, a wholly-owned subsidiary of LKL International, had on 27 July 2018 being awarded a contract for the supply and delivery of medical/healthcare beds and medical peripherals by Ministry of Health of Uganda (“the Contract”). 2. THE CONTRACT VALUE The Contract value is US Dollars 2.8 million, which is approximately RM11.4 million (based on Bank Negara Malaysia’s exchange rate of USD1:RM4.064 as at 27 July 2018). 3. DURATION OF CONTRACT The contract is for a period of one (1) year commencing from 1 August 2018 to 1 August 2019. 4. FINANCIAL EFFECTS The Contract will not have material effect on the net assets and gearing of the Company for the financial year ending 30 April 2019 and is expected to contribute positively to the earnings of the Company over the duration of the Contract. 5. THE RISKS IN RELATION TO THE CONTRACT The risks mainly relate to meeting of delivery deadlines imposed by customer which are considered normal operational risks. 6. DIRECTORS AND/OR MAJOR SHAREHOLDERS’ INTEREST None of the Directors and/or major shareholders of LKL International have any interest, whether direct or indirect, in the Contract. 7. STATEMENT OF DIRECTORS The Board of Directors of the Company is of the opinion that the Contract is in the ordinary course of business and is in the best interests of the Company. This announcement is dated 30 July 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "COMPANY")- LETTER OF AWARD TO LKL ADVANCE METALTECH SDN. BHD. ("LKLAM"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, FOR THE SUPPLY, DELIVERY, INSTALLATION, TESTING AND COMMISSIONING OF MEDICAL/HEALTHCARE BEDS AND MEDICAL EQUIPMENT
1. INTRODUCTION The Board of Directors of LKL International is pleased to announce that LKLAM, a wholly-owned subsidiary of LKL International, had on 31 July 2018 accepted a Letter of Award from Selgate Rawang Hospital Sdn. Bhd. for the supply, delivery, installation, testing and commission of medical/healthcare beds and medical equipment for a private medical hospital to be constructed in Mukim Rawang, Selangor (“the Contract”). 2. THE CONTRACT VALUE The Contract value is RM6,196,825.30 (Ringgit Malaysia Six Million One Hundred Ninety Six Thousand Eight Hundred Twenty Five and Sen Thirty Only). 3. DURATION OF CONTRACT The Contract shall commence after completion of the construction of the private medical hospital, which is expected to be in the fourth quarter of 2019. 4. FINANCIAL EFFECTS The Contract will not have any effect on the net assets and gearing of the Company for the financial year ending 30 April 2019 and is expected to contribute positively to the earnings of the Company over the duration of the Contract. 5. THE RISKS IN RELATION TO THE CONTRACT The risks mainly relate to meeting of delivery deadlines imposed by customer which are considered normal operational risks. 6. DIRECTORS AND/OR MAJOR SHAREHOLDERS’ INTEREST None of the Directors and/or major shareholders of LKL International have any interest, whether direct or indirect, in the Contract. 7. STATEMENT OF DIRECTORS The Board of Directors of the Company is of the opinion that the Contract is in the ordinary course of business and is in the best interests of the Company. This announcement is dated 1 August 2018.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Jul 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Jul 2018	31 Jul 2017	31 Jul 2018	31 Jul 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	7,769	4,825	7,769	4,825
2	Profit/(loss) before tax	67	-912	67	-912
3	Profit/(loss) for the period	33	-912	33	-912
4	Profit/(loss) attributable to ordinary equity holders of the parent	28	-859	28	-859
5	Basic earnings/(loss) per share (Subunit)	0.01	-0.20	0.01	-0.20
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1400		0.1400

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "COMPANY")- LKL INTERNATIONAL INKS COLLABORATIVE MEMORANDUM OF UNDERSTANDING ("MOU") TO MARKET NEW MEDICAL DEVICE
We are pleased to attach a press release dated 26 September 2018 entitled "LKL International inks collaborative MoU to market new medical device". Please refer attachment below. This announcement is dated 26 September 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5924169

Attachments LKL_FKSMedicalCare_MoU_PR_Final.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- MEMORANDUM OF UNDERSTANDING BETWEEN LKL ADVANCE METALTECH SDN. BHD., THE WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND FKS MEDICAL CARE SDN. BHD.
1. INTRODUCTION The Board of Directors of LKL International ("Board") wishes to announce that its wholly-owned subsidiary, LKL Advance Metaltech Sdn. Bhd. (“LKLAM”), had entered into a Memorandum of Understanding (“MOU”) with FKS Medical Care Sdn. Bhd. (“FKS”). 2. BACKGROUND OF THE MOU LKLAM is in the business of provision of medical/healthcare beds, peripherals and accessories, and is one of the largest local healthcare product manufacturers in Malaysia. LKLAM provides diverse product range to hospitals, medical centres, as well as other healthcare-related facilities such as clinics and specialist institutions. FKS is a subsidiary of FKS-Life & Health Medical Care Inc., a reputable medical appliance and device manufacturer and distributor based in California, United States. Both LKLAM and FKS envisage a mutually beneficial arrangement to co-operate in the market development of dermaPACE® by Sanuwave Health Inc., an advanced medical device used for treating acute and chronic wounds. 3. SALIENT TERMS OF THE MOU The MOU does not constitute a binding or enforceable agreement between LKLAM and FKS, but is aimed to provide a basic framework of collaboration between the parties to co-operate for the promoting and marketing of dermaPACE® in Malaysia. The term of the MOU will be for two years. 4. FINANCIAL EFFECTS The execution of the MOU is not expected to have any material effect on the net assets and gearing of the Company for the financial year ending 30 April 2019. Should the collaboration materialise, it is expected to contribute positively to the earnings of the Company. 5. RISK FACTORS The Board is of the view that the risk factors involved in this MOU is minimal and in the event the Company enters into a normal business arrangement, it will exercise due care in considering the associated risks and benefits, and will take appropriate measures in planning the successful implementation of the MOU. 6. APPROVAL REQUIRED The MOU is entered into in the ordinary course of business of the Company and does not require approval of the Company’s shareholders and/or any regulatory authorities. 7. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED TO THEM None of the directors, major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the MOU. 8. STATEMENT OF DIRECTORS The Board, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the ordinary course of business and is in the best interests of the Company. 9. DOCUMENT FOR INSPECTION The MOU will be made available for inspection at the registered office of the Company at Third Floor, No. 79 (Room A), Jalan SS21/60, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan, during normal business hours (except public holidays) for a period of three (3) months from the date of this announcement. This announcement is dated 28 September 2018.

icy97

医疗家具领导者LKL国际成功开拓海外版图
http://www.enanyang.my/news/20181016/【南洋品牌奖视频】医疗家具领导者-lkl国际-成功开/

icy97

icy97

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- MEMORANDUM OF UNDERSTANDING BETWEEN LKL ADVANCE METALTECH SDN. BHD. ("LKLAM"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND AGROW CORPORATION SDN. BHD. ("AGROW")
1.   INTRODUCTION The Board of Directors of LKL International (“Board”) wishes to announce that its wholly-owned subsidiary, LKLAM, had on 4 December 2018 entered into a Memorandum of Understanding (“MOU”) with AGROW. 2.   BACKGROUND OF THE MOU LKLAM is in the business of provision of medical/healthcare beds, peripherals and accessories, and is one of the largest local healthcare product manufacturers in Malaysia. LKLAM provides diverse product range to hospitals, medical centres, as well as other healthcare-related facilities such as clinics and specialist institutions. AGROW is a wholly-owned subsidiary of Agrow Malaysia Sdn. Bhd., which in turn is a wholly-owned subsidiary of OCB Berhad, a listed company on the Main Market of Bursa Malaysia Securities Berhad. AGROW is a specialist in building materials, supplying a wide range of international and local branded sanitary wares, bathroom wares, bathroom fittings, bathroom accessories, ironmongery, doors and other quality building products and providing services to all stakeholders in the building and construction industry. Institutional buildings, hospital/laboratory projects and custom designed items are also other area of AGROW’s specialty. Both LKLAM and AGROW envisage a mutually beneficial arrangement to cooperate in the market development of BREATHAIR merchandise, an advanced washable cushion material with high level of air and water permeability, cushioning characteristics, durability, safe and anti-bacterial properties. BREATHAIR merchandise is widely used in hospitals and healthcare facilities. 3.   SALIENT TERMS OF THE MOU The MOU does not constitute a binding or enforceable agreement between LKLAM and AGROW, but is aimed to provide a basic framework of collaboration between the parties to cooperate for the promoting and marketing of BREATHAIR merchandise in the global market. LKLAM shall be responsible for applying the certificate necessarily for the sale of BREATHAIR merchandise in the global market on behalf of the manufacturer. The term of the MOU will be for a period of two years. 4.   FINANCIAL EFFECTS The execution of the MOU is not expected to have any material effect on the net assets and gearing of the Company for the financial year ending 30 April 2019. Should the collaboration materialise, it is expected to contribute positively to the earnings of the Company. 5.   RISK FACTORS The Board is of the view that the risk factors involved in this MOU at this juncture is minimal and in the event the Company enters into a normal business arrangement, it will exercise due care in considering the associated risks and benefits, and will take appropriate measures in planning the successful implementation of the MOU vis-à-vis its current business operations. 6.   APPROVAL REQUIRED The MOU is not subject to the approval of the Company’s shareholders and/or any regulatory authorities. 7.   INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED TO THEM None of the directors, major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the MOU. 8.   STATEMENT OF DIRECTORS The Board, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the best interests of the Company. 9.   DOCUMENT FOR INSPECTION The MOU will be made available for inspection at the registered office of the Company at Third Floor, No. 79 (Room A), Jalan SS21/60, Damansara Utama, 47400 Petaling Jaya, Selangor Darul Ehsan, during normal business hours (except public holidays) for a period of three (3) months from the date of this announcement. This announcement is dated 4 December 2018.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Oct 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Oct 2018	31 Oct 2017	31 Oct 2018	31 Oct 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	9,481	7,166	17,250	11,991
2	Profit/(loss) before tax	218	287	285	-625
3	Profit/(loss) for the period	133	287	166	-625
4	Profit/(loss) attributable to ordinary equity holders of the parent	113	378	141	-481
5	Basic earnings/(loss) per share (Subunit)	0.03	0.09	0.03	-0.11
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1400		0.1400

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

LKL INTERNATIONAL BERHAD

Particulars of Substantial Securities Holder

Name	AI CAPITAL SDN. BHD.
Address	Third Floor, No. 79 (Room A) Jalan SS 21/60, Damansara Utama Petaling Jaya 47400 Selangor Malaysia.
Company No.	663846-T
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary shares
Name & address of registered holder	AI Capital Sdn. Bhd.Third Floor, No. 79 (Room A), Jalan SS 21/60, Damansara Utama, 47400 Petaling Jaya, Selangor.

Date interest acquired & no of securities acquired
Date interest acquired	24 Dec 2018
No of securities	28,771,990
Circumstances by reason of which Securities Holder has interest	Acquisition of shares via married deal
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	28,771,990
Direct (%)	6.71
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Date of notice	28 Dec 2018
Date notice received by Listed Issuer	28 Dec 2018

icy97

Name	MR TAN CHUAN HOCK
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	24 Dec 2018	28,771,990	Disposed	Direct Interest
	Name of registered holder	Tan Chuan Hock
	Address of registered holder	No. 2, Jalan 12/15, 46200 Petaling Jaya, Selangor
	Description of "Others" Type of Transaction
2	24 Dec 2018	28,771,990	Acquired	Indirect Interest
	Name of registered holder	AI Capital Sdn. Bhd.
	Address of registered holder	Third Floor, No. 79 (Room A), Jalan SS 21/60, Damansara Utama, 47400 Petaling Jaya, Selangor
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	1) Disposal of 28,771,990 ordinary shares via married deal2) Acquisition of 28,771,990 ordinary shares by AI Capital Sdn. Bhd. via married deal
Nature of interest	Direct and Indirect Interest
Direct (units)	0
Direct (%)	0
Indirect/deemed interest (units)	28,771,990
Indirect/deemed interest (%)	6.71
Total no of securities after change	28,771,990
Date of notice	28 Dec 2018
Date notice received by Listed Issuer	28 Dec 2018

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- CONTRACT AWARDED TO LKL ADVANCE METALTECH SDN. BHD. ("LKLAM"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, FOR THE SUPPLY, DELIVERY, INSTALLATION, TESTING AND COMMISSIONING OF MEDICAL/HEALTHCARE BEDS AND MEDICAL EQUIPMENT
1. INTRODUCTION The Board of Directors of LKL International is pleased to announce that LKLAM, a wholly-owned subsidiary of LKL International, had on 28 December 2018 being awarded a contract by VAMED Engineering GmbH for the supply, delivery, installation, testing and commission of medical/healthcare beds and medical equipment for a teaching hospital and medical academic centre to be constructed in Mukim Jeram, Selangor (“the Contract”). 2. THE CONTRACT VALUE The Contract value is RM4,845,000 (Ringgit Malaysia Four Million Eight Hundred Forty Five Thousand Only). 3. DURATION OF CONTRACT The Contract shall commence after completion of the construction of the teaching hospital and medical academic centre, which is expected to be completed in the third quarter of 2019. 4. FINANCIAL EFFECTS The Contract will not have any material effect on the net assets and gearing of the Company for the financial year ending 30 April 2019 and is expected to contribute positively to the earnings of the Company over the duration of the Contract. 5. THE RISKS IN RELATION TO THE CONTRACT The risks mainly relate to meeting of delivery deadlines imposed by customer which are considered normal operational risks. 6. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSONS CONNECTED TO THEM None of the Directors, major shareholders and/or persons connected to them have any interest, whether direct or indirect, in the Contract. 7. STATEMENT OF DIRECTORS The Board of Directors of the Company is of the opinion that the acceptance of the Contract is in the best interests of the Company. This announcement is dated 31 December 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- DISTRIBUTORSHIP AGREEMENT BETWEEN MEDIK GEN SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND BENQ MEDICAL TECHNOLOGY CORPORATION
The Board of Directors of LKL International wishes to announce that Medik Gen Sdn. Bhd., the wholly-owned subsidiary of the Company had on 19 March 2019 entered into a distributorship agreement ("DA") with BenQ Medical Technology Corporation ("BenQ") to carry out the business of distributing BenQ's ultrasound system, surgical light and surgical table, and its related spare parts and software in Malaysia. Please refer to the attachment for the details of the DA. This announcement is dated 19 March 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6098765

Attachments Distributorship Agreement with BenQ.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Jan 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Jan 2019	31 Jan 2018	31 Jan 2019	31 Jan 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	11,086	10,246	28,336	22,237
2	Profit/(loss) before tax	23	1,064	308	439
3	Profit/(loss) for the period	148	838	314	213
4	Profit/(loss) attributable to ordinary equity holders of the parent	112	893	253	412
5	Basic earnings/(loss) per share (Subunit)	0.03	0.21	0.06	0.10
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1400		0.1400

icy97

icy97 发表于 3-1-2019 08:08 AM

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- JOINT VENTURE AGREEMENT BETWEEN MEDIK GEN SDN. BHD. ("MGEN"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND AGROW CORPORATION SDN. BHD. ("AGROW")
Reference is made to the announcement of the Company dated 4 December 2018 whereat a Memorandum of Understanding was entered between LKL Advance Metaltech Sdn. Bhd., a wholly-owned subsidiary of LKL International, and Agrow to cooperate in the market development of BREATHAIR merchandise. The Board of Directors of LKL International wishes to announce that its wholly-owned subsidiary, MGen, had on 10 April 2019 entered into a Shareholders’ Agreement with Agrow to form and incorporate a joint venture company solely to carry out the business of promoting, marketing, distributing and sales of selected branded medical devices within Malaysia. (“Proposed Joint Venture”) Please refer to the attachment for the details of the Proposed Joint Venture. This announcement is dated 10 April 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6121333

Attachments LKL - JV Agreement between MGen_Agrow.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- DISTRIBUTORSHIP AGREEMENT BETWEEN MEDIK GEN SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND BENQ ASIA PACIFIC CORPORATION
The Board of Directors of LKL International wishes to announce that Medik Gen Sdn. Bhd., the wholly-owned subsidiary of the Company had on 12 April 2019 entered into a distributorship agreement ("DA") with BenQ Asia Pacific Corporation ("BenQ Asia") to carry out the business of distributing BenQ Asia's medical displays and its related spare parts and software. Please refer to the attachment for the details of the DA. This announcement is dated 12 April 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6124193

Attachments LKL - MGen_BenQAsia_DA.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- DISTRIBUTORSHIP AGREEMENT BETWEEN MEDIK GEN SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, AND LILY MEDICAL CORPORATION
The Board of Directors of LKL International wishes to announce that Medik Gen Sdn. Bhd., the wholly-owned subsidiary of the Company had on 12 April 2019 entered into a distributorship agreement ("DA") with Lily Medical Corporation ("Lily") to carry out the business of distributing Lily's disposal medical devices and its related spare parts. Please refer to the attachment for the details of the DA. This announcement is dated 12 April 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6124185

Attachments LKL - MGen_Lily_DA.pdf

icy97

icy97 发表于 19-4-2019 07:06 AM
http://www.bursamalaysia.com/market/listed-companies/company-announcements/6121333

Type	Announcement
Subject	OTHERS
Description	LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR "THE COMPANY")- INCORPORATION OF LKL AGROW HEALTHTECH SDN. BHD., A JOINT VENTURE COMPANY
Further to the announcement made on 10 April 2019, the Board of Directors of the Company wishes to announce that a joint venture company namely LKL Agrow Healthtech Sdn. Bhd. (“LKL Agrow Healthtech”) has been incorporated on 15 April 2019 pursuant to the Shareholders’ Agreement (“JVSA”) entered into between Medik Gen Sdn. Bhd. (“MGen”), a wholly-owned subsidiary of LKL International, and Agrow Corporation Sdn. Bhd. (“Agrow”). The intended principal activity of LKL Agrow Healthtech is solely to carry out the business of promoting, marketing, distributing and sales of selected branded medical devices within Malaysia. LKL Agrow Healthtech has an initial issued share capital of Ringgit Malaysia Two Only (RM2.00) comprising two (2) ordinary shares which are equally subscribed by MGen and Agrow in accordance with the terms of the JVSA. The registered address of LKL Agrow Healthtech is D117, Block D, First Floor, Kelana Square, 17 Jalan SS 7/26, Kelana Jaya, 47301 Petaling Jaya, Selangor Darul Ehsan. None of the Directors, major shareholders and/or persons connected to them has any interest, whether direct or indirect, in LKL Agrow Healthtech. This announcement is dated 15 April 2019.